Ivonescimab Beats Immunotherapy in Lung Cancer: Inside the HARMONi-6 Trial That Rewrote the Standard of Care

A bispecific antibody that simultaneously targets PD-1 and VEGF just beat the standard immunotherapy regimen head-to-head in overall survival. It is the first time any drug has achieved this milestone in first-line lung cancer.

Presented By Our Partners

For nearly a decade, immunotherapy has been the most consequential development in lung cancer treatment. Since checkpoint inhibitors entered clinical practice around 2016, the survival curves have shifted dramatically for patients who once had few options. But the scientific premise underlying all of these drugs has remained essentially the same: block the PD-1 pathway, reinvigorate exhausted T cells, and let the immune system do what it evolved to do. That era is not over, but it now has serious competition.

At the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, Professor Shun Lu of Shanghai Chest Hospital presented results from the HARMONi-6 Phase III trial that will almost certainly reshape how oncologists approach advanced squamous non-small cell lung cancer. Ivonescimab, a first-in-class bispecific antibody designed by Akeso Biopharma to block both PD-1 and VEGF simultaneously within a single molecule, reduced the risk of death by 34 percent compared to tislelizumab, one of the most widely used PD-1 inhibitors in current clinical practice. The results were simultaneously published in The Lancet.

Lung cancer kills more people globally than any other cancer, approximately 1.8 million deaths per year according to the World Health Organization, and squamous NSCLC represents roughly a quarter of all cases. The fact that ivonescimab is the first regimen ever to demonstrate clinical superiority over an active PD-1 inhibitor control arm in first-line lung cancer is not a marginal improvement. It is a paradigm shift.

The Drug That Does Two Jobs at Once

Understanding why ivonescimab performs differently from standard checkpoint inhibitors requires a look at the biology of the tumor microenvironment, the hostile terrain in and around a tumor where cancer cells, immune cells, blood vessels, and signaling molecules compete for dominance.

Standard PD-1 inhibitors like pembrolizumab, nivolumab, and tislelizumab work by blocking the PD-1 receptor on T cells. Cancer cells exploit this pathway by expressing its ligands (PD-L1 and PD-L2) to effectively cloak themselves from immune attack. By interrupting this immune checkpoint, PD-1 inhibitors restore the ability of T cells to recognize and kill tumor cells. It is a powerful mechanism, but it addresses only one of several ways tumors evade the immune system.

VEGF, or vascular endothelial growth factor, is a separate and underappreciated problem. Tumors secrete VEGF to stimulate the growth of new blood vessels, a process called angiogenesis, which not only feeds the tumor with nutrients and oxygen but actively creates an immunosuppressive microenvironment. High VEGF levels correlate with increased infiltration of regulatory T cells and myeloid-derived suppressor cells, both of which suppress anti-tumor immune responses. In other words, VEGF does not just build the tumor’s blood supply. It also helps the tumor hide from the immune system.

Ivonescimab was engineered to hit both targets with a single molecule. Its tetravalent bispecific structure carries two binding arms for PD-1 and two for VEGF. The molecular design enables what researchers call cooperative binding: when VEGF is present, the molecule’s affinity for PD-1 increases by more than 18-fold. Because both PD-1 and VEGF are highly expressed in tumor tissue compared to healthy tissue, ivonescimab preferentially concentrates where it needs to be, within the tumor microenvironment itself, while reducing the systemic anti-VEGF side effects typically associated with drugs like bevacizumab, including hypertension, bleeding risk, and wound healing complications.

The theoretical case for this dual blockade has existed for years. HARMONi-6 is the first large Phase III trial to prove it delivers superior survival over best-in-class immunotherapy alone.

The Trial That Changed the Equation

HARMONi-6 was a randomized Phase III study that enrolled 532 patients with previously untreated advanced squamous NSCLC, the most common form of lung cancer in current heavy and former smokers. Patients were assigned in a 1:1 ratio to receive either ivonescimab at 20 mg/kg every three weeks or tislelizumab at 200 mg every three weeks, with both arms combined with four cycles of paclitaxel and carboplatin chemotherapy before transitioning to maintenance monotherapy. Randomization was stratified by disease stage and PD-L1 tumor proportion score.

The trial was designed with a hierarchical statistical testing procedure: progression-free survival was tested first, and overall survival was formally assessed only after the PFS endpoint was confirmed. This is a rigorous regulatory standard that protects against inflated Type I error rates in trials testing multiple endpoints, and HARMONi-6 met both bars cleanly. The prespecified interim PFS analysis had already shown that ivonescimab kept cancer from progressing for approximately 11 months compared to roughly 9 months with tislelizumab. The OS analysis presented at ASCO 2026 is the definitive survival verdict.

The patient population was challenging and representative of real-world squamous NSCLC practice. Approximately 63 percent of enrolled patients had centrally located squamous tumors, which are typically harder to treat surgically and are associated with a higher risk of complications. Nearly 39 percent had a PD-L1 tumor proportion score below 1 percent, meaning their tumors expressed very low levels of the protein that PD-1 inhibitors conventionally rely on to predict benefit. And 33.8 percent had multi-site metastases, liver metastases, or brain metastases at baseline, disease characteristics that historically predict poor outcomes with standard therapy. This was not an enriched, best-case population. It was a realistic cross-section of the patients oncologists encounter in practice.

The Numbers That Matter

At the data cutoff of February 27, 2026, with a median follow-up of 21.4 months, ivonescimab delivered a median overall survival of 27.9 months compared to 23.7 months with tislelizumab. The hazard ratio was 0.66 (95% confidence interval, 0.50 to 0.87; one-sided P=0.0017), a result that met the prespecified efficacy boundary of P less than 0.0049 with substantial room to spare.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

To put 27.9 months in historical context: in the era before immunotherapy, median overall survival in advanced squamous NSCLC with first-line platinum doublet chemotherapy rarely exceeded 10 to 12 months. The introduction of pembrolizumab and similar agents pushed that figure toward 16 to 22 months in broad populations. Ivonescimab extends the median survival curve by an additional four months over a currently approved and actively used immunotherapy comparator, and it does so against that stronger baseline rather than against historical chemotherapy data.

The Kaplan-Meier survival curves separated early and continued to diverge across the duration of follow-up, a pattern oncologists regard as evidence of durable benefit rather than a transient early advantage. At 18 months, the OS rate with ivonescimab was approximately 59 percent versus 47 percent with tislelizumab. The upper confidence interval for ivonescimab’s median OS was listed as “not evaluable” at the time of the data cutoff, indicating that the median had not been reached for a meaningful proportion of surviving patients. In practical terms, this means the true benefit likely exceeds what the current data show.

Safety was manageable and consistent with the prior ivonescimab safety database, with no new signals observed. This is a key consideration when comparing bispecific antibodies to combination regimens using two separate agents, which often carry higher combined toxicity burdens.

Why Dual Blockade Works Where Single Blockade Falls Short

The mechanistic story behind ivonescimab’s performance connects directly to the cooperative biology of tumor immune evasion and explains why simply combining a PD-1 inhibitor with a separate anti-VEGF agent does not fully replicate what a bispecific achieves.

In tumors with high VEGF expression, the immune microenvironment is actively hostile to T cell activity. VEGF drives the formation of abnormal, leaky tumor blood vessels that create hypoxic pockets, and hypoxia directly suppresses cytotoxic T cell function and survival. VEGF also promotes the differentiation of monocytes into immunosuppressive tumor-associated macrophages and facilitates the recruitment of regulatory T cells. When you block PD-1 alone in this setting, you partially reinvigorate T cells, but you send them into a microenvironment that remains structurally hostile to their survival and killing activity.

Anti-VEGF therapy addresses the other half of this problem. By normalizing tumor vasculature, VEGF blockade improves oxygen delivery within the tumor, reduces the accumulation of immunosuppressive cell types, and creates a more permissive environment for T cell infiltration and cytotoxic activity. Preclinical studies have demonstrated synergistic anti-tumor effects when PD-1 and VEGF blockade are combined, effects that exceed either agent alone.

What ivonescimab adds beyond a simple co-administration of two separate drugs is molecular architecture that concentrates both blocking activities precisely within the tumor microenvironment, leveraging the cooperative binding enhancement triggered by VEGF presence. A 2025 review article in Antibody Therapeutics published through Oxford Academic analyzed the structural properties of PD-1/VEGF bispecifics and concluded that the cooperative binding mechanism and preferential TME accumulation represent genuine pharmacological advantages over combination approaches that rely on independent pharmacokinetics for each agent.

The PD-L1-Low Problem, Potentially Solved

One of the most clinically significant findings from HARMONi-6 is the performance of ivonescimab in patients with PD-L1 tumor proportion scores below 1 percent, a subgroup representing approximately 40 percent of the trial population that has historically derived the least benefit from checkpoint inhibitors.

Standard PD-1 monotherapy is most effective in tumors with high PD-L1 expression, because PD-L1 is what allows cancer cells to activate the PD-1 checkpoint on T cells in the first place. In PD-L1-low tumors, this checkpoint is less active, and checkpoint inhibitors correspondingly have less to unlock. Many oncologists treat PD-L1 TPS below 1 percent as a negative predictive biomarker that qualifies the expectations they set with patients about immunotherapy benefit.

In HARMONi-6, the OS benefit with ivonescimab over tislelizumab was fully consistent regardless of PD-L1 expression. In the PD-L1 TPS less than 1 percent subgroup, median OS with ivonescimab had not been reached at the time of analysis, compared to 18.6 months with tislelizumab (HR, 0.64; 95% CI, 0.43 to 0.96). In the PD-L1-high subgroup, median OS was similarly not reached with ivonescimab versus 27.3 months with tislelizumab (HR, 0.68; 95% CI, 0.46 to 0.99). The benefit was numerically similar in both populations, and in PD-L1-low patients, the absolute difference in median OS was even larger.

This finding implies that ivonescimab’s anti-VEGF component is contributing meaningfully to the observed survival benefit in low PD-L1 tumors, where PD-1 blockade alone would be expected to produce a muted response. If this pattern holds in larger datasets and post-marketing studies, it could simplify treatment decision-making by reducing the reliance on PD-L1 testing as a patient selection tool and extending survival benefits to a population that has been underserved by the immunotherapy revolution of the past decade.

A Bispecific Pipeline Takes Shape

The HARMONi-6 results do not exist in isolation. They are part of a broader shift in cancer drug development toward molecules that address multiple tumor biology targets simultaneously, rather than sequentially or in parallel combination.

Ivonescimab itself has an active development program across multiple tumor types. Earlier Phase III data from the HARMONi-A trial in patients with pretreated EGFR-mutated NSCLC demonstrated improved progression-free survival in a setting where PD-1 inhibitors have historically shown minimal activity. That data supported the FDA’s acceptance of a Biologics License Application for ivonescimab in the EGFR-mutant NSCLC indication, which is currently under regulatory review. At ASCO 2026, Phase II data were also presented showing activity in first-line metastatic colorectal cancer, suggesting the PD-1/VEGF bispecific class may have applicability well beyond thoracic oncology.

More broadly, bispecific antibody design is gaining ground across oncology. Agents combining PD-L1 blockade with anti-LAG-3, PD-1 with TIM-3, and CTLA-4 with PD-L1 are progressing through clinical development, each attempting to dismantle multiple immune evasion mechanisms simultaneously. The HARMONi-6 overall survival data provide the strongest prospective clinical validation to date that this design philosophy can deliver meaningful, practice-changing gains over the previous generation of single-target immunotherapy.

Regulatory watchers will now focus on the timeline for ivonescimab’s FDA review in the squamous NSCLC setting. Given the size of the survival effect, the Lancet co-publication, and the established precedent from earlier ivonescimab approvals in other markets, the approval pathway in the United States is likely to move with urgency.

Lung Cancer and the Longevity Landscape

Lung cancer’s position among the primary chronic disease threats to longevity means that advances in its treatment carry significance beyond the oncology community. It remains the single largest contributor to cancer mortality worldwide, claiming more lives annually than colorectal, breast, and prostate cancers combined.

The evolution from single-target checkpoint inhibition to dual-mechanism bispecific antibodies mirrors a broader logic that is showing up across longevity medicine: rather than disrupting one pathway and waiting to see what compensates, next-generation therapies are being designed to preemptively address the compensatory mechanisms that disease uses to escape. This systems biology approach is visible in metabolic medicine, neurodegeneration research, and cardiovascular therapy as well. The recognition that cancer, like most chronic disease, is rarely driven by a single mechanism is reshaping how drug developers construct their molecules from the earliest stages of design.

For patients living with squamous NSCLC, the practical implication of HARMONi-6 is a meaningfully higher proportion of patients alive at 18 months and an extension of median survival beyond what was achievable with any prior first-line regimen. For the broader science of healthy longevity, it represents proof of concept that the bispecific design strategy delivers on its promise in the hardest clinical test available: overall survival in a randomized Phase III trial against an active, proven comparator.

What This Means For You

If you or someone you care about is facing a diagnosis of advanced squamous non-small cell lung cancer, the HARMONi-6 data are a genuine reason for hope. Ivonescimab is not yet FDA-approved for this indication, but the Lancet co-publication and ASCO plenary designation significantly accelerate the regulatory pathway. It is worth asking your oncologist directly about ivonescimab’s current approval status, whether expanded access programs exist, and whether any ongoing clinical trials are enrolling in your region.

For patients who have been told their tumor is PD-L1-low or PD-L1-negative, the HARMONi-6 subgroup data are especially relevant. Prior conversations with oncologists in this setting often carried qualified expectations about immunotherapy benefit. The bispecific mechanism appears to substantially reduce the predictive weight of that biomarker, which could change both the treatment conversation and the clinical options available to you.

For readers focused on long-term health and cancer prevention, the data reinforce several high-leverage principles. Lung cancer risk reduction remains one of the highest-yield prevention investments available: tobacco cessation dramatically reduces squamous NSCLC risk, and low-dose CT screening for current or former heavy smokers remains significantly underutilized despite well-established guidelines. Regular aerobic exercise, particularly training that maintains or builds cardiovascular fitness, is associated in multiple large studies with reduced cancer incidence and improved outcomes in patients who receive immunotherapy. The immune system that ivonescimab is working to reinvigorate functions better, and responds more robustly to immunotherapy, in people with lower baseline systemic inflammation and higher cardiorespiratory capacity.

The science of lung cancer treatment is moving forward faster than at any previous moment in the disease’s history. HARMONi-6 is the most compelling evidence yet that the next standard of care has arrived.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.